ATE239790T1 - Antikörper gegen cd40-l - Google Patents

Antikörper gegen cd40-l

Info

Publication number
ATE239790T1
ATE239790T1 AT98113461T AT98113461T ATE239790T1 AT E239790 T1 ATE239790 T1 AT E239790T1 AT 98113461 T AT98113461 T AT 98113461T AT 98113461 T AT98113461 T AT 98113461T AT E239790 T1 ATE239790 T1 AT E239790T1
Authority
AT
Austria
Prior art keywords
antibodies against
immunogen
disclosed
isolated antibody
antibody immunoreactive
Prior art date
Application number
AT98113461T
Other languages
German (de)
English (en)
Inventor
Richard J Armitage
William C Fanslow
Melanie K Spriggs
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE239790(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE239790T1 publication Critical patent/ATE239790T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98113461T 1991-10-25 1992-10-23 Antikörper gegen cd40-l ATE239790T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US80572391A 1991-12-05 1991-12-05

Publications (1)

Publication Number Publication Date
ATE239790T1 true ATE239790T1 (de) 2003-05-15

Family

ID=27120174

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92925017T ATE274055T1 (de) 1991-10-25 1992-10-23 Neue cytokine
AT98113461T ATE239790T1 (de) 1991-10-25 1992-10-23 Antikörper gegen cd40-l

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT92925017T ATE274055T1 (de) 1991-10-25 1992-10-23 Neue cytokine

Country Status (12)

Country Link
EP (2) EP0897983B1 (OSRAM)
JP (2) JP3308534B2 (OSRAM)
KR (1) KR100283541B1 (OSRAM)
AT (2) ATE274055T1 (OSRAM)
AU (1) AU661360B2 (OSRAM)
CA (2) CA2312667C (OSRAM)
DE (2) DE69233402T3 (OSRAM)
DK (3) DK0667901T4 (OSRAM)
ES (2) ES2227513T5 (OSRAM)
FI (2) FI116850B (OSRAM)
NO (2) NO317625B1 (OSRAM)
WO (1) WO1993008207A1 (OSRAM)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DE69433399T2 (de) * 1993-01-22 2004-10-14 Immunex Corp., Seattle Detektion und behandlung von mutationen in einem gen für einen cd40-liganden
DE69423806T2 (de) * 1993-01-22 2000-08-17 Kanegafuchi Chemical Ind Therapeutisches Agens für NIDDM
CN100341896C (zh) 1993-09-02 2007-10-10 达特茅斯学院理事 抗gp39抗体及其应用
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
EP0742721B1 (en) * 1993-09-02 1999-05-06 Trustees of Dartmouth College Methods of prolonged suppression of humoral immunity
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
MX9605088A (es) 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
JP3657271B2 (ja) * 1995-03-01 2005-06-08 イミュネックス・コーポレーション 病原性または日和見感染性生物に感染した哺乳動物の治療のための組成物
WO1996028568A1 (en) 1995-03-13 1996-09-19 The Regents Of The University Of Michigan Cd40 binding compositions and methods of using same
IL122174A (en) * 1995-06-07 2004-07-25 Immunex Corp Dna encoding a cd40l mutein and a cd40l polypeptide encoded by said dna
JPH11508262A (ja) * 1995-06-22 1999-07-21 バイオジェン，インコーポレイテッド Ｃｄ４０リガンドのフラグメントの結晶およびその使用
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EP0910474B1 (en) * 1996-06-14 2004-03-24 University of Washington Absorption-enhanced differential extraction method
WO1998001538A1 (en) * 1996-07-10 1998-01-15 Immunex Corporation Method of activating dendritic cells
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DE69939822D1 (de) 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
DK1783222T3 (da) * 1998-10-23 2012-07-09 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
WO2000063395A1 (en) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
AU6934600A (en) 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US6797263B2 (en) 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
ATE541860T1 (de) 2000-10-02 2012-02-15 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40 zur therapie von b- zell tumoren
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
US20050054565A1 (en) * 2001-07-31 2005-03-10 John Lucas Agonists and antagonists of moxifin for the treatment of metabolic disorders
JP4266825B2 (ja) 2001-09-20 2009-05-20 イミユネツクス・コーポレイシヨン ヘテロマーポリペプチドを発現する細胞の選択
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
MXPA05008523A (es) 2003-02-14 2005-10-20 Biogen Idec Inc Un casete de expresion y vector para la expresion transitoria o estable de moleculas exogenas.
KR20070047327A (ko) 2004-07-26 2007-05-04 비오겐 아이덱 엠에이 아이엔씨. 항-ｃｄ154 항체
WO2006042177A2 (en) 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
EP1805320B1 (en) 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
EP2500413A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
ES2520026T3 (es) 2006-09-18 2014-11-11 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para potenciar respuestas inmunitarias
AU2008298904B2 (en) 2007-09-14 2014-10-16 Amgen Inc. Homogeneous antibody populations
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
CA3051748C (en) 2007-11-01 2022-07-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
RU2502800C2 (ru) 2008-01-15 2013-12-27 Эббви Инк. Усовершенствованные векторы экспрессии млекопитающих и их применение
PT2501822T (pt) 2009-11-17 2017-10-18 Squibb & Sons Llc Métodos para produção de proteínas melhorada
PL2525817T3 (pl) 2010-01-21 2018-01-31 Univ Arkansas Wektory szczepionkowe i sposoby wzmacniania odpowiedzi immunologicznych
EA030793B1 (ru) 2010-06-09 2018-09-28 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Рекомбинантный вакцинный вектор против инфекции campylobacter и способы усиления иммунного ответа на campylobacter и повышения устойчивости к инфекции campylobacter
JP6532407B2 (ja) 2013-02-14 2019-06-19 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
EP3331563B1 (en) 2015-08-05 2023-04-19 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
CA3024027A1 (en) 2016-05-11 2017-11-16 Amgen Inc. Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
JP7128195B2 (ja) 2017-02-27 2022-08-30 シャタック ラボ，インコーポレイテッド 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
EP3585409A4 (en) * 2017-02-27 2020-12-02 Shattuck Labs, Inc. CHEMERICAL PROTEINS BASED ON CSF1R

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
DE69233402T2 (de) 2005-09-15
DK0822199T3 (da) 2004-12-27
FI116828B (fi) 2006-03-15
NO320073B1 (no) 2005-10-17
DE69233402D1 (de) 2004-09-23
FI941837A0 (fi) 1994-04-20
NO980030L (no) 1998-01-05
JPH07504083A (ja) 1995-05-11
AU3122693A (en) 1993-05-21
DK0897983T3 (da) 2003-08-11
DK0667901T4 (da) 2008-11-10
ES2227513T5 (es) 2009-04-01
DE69233051D1 (de) 2003-06-12
NO980030D0 (no) 1998-01-05
DK0667901T3 (da) 2004-12-27
ES2227513T3 (es) 2005-04-01
EP0667901A1 (en) 1995-08-23
JPH10150994A (ja) 1998-06-09
DE69233051T2 (de) 2004-03-11
EP0667901B2 (en) 2008-10-15
HK1019343A1 (en) 2000-02-03
NO941422L (OSRAM) 1994-06-27
CA2312667A1 (en) 1993-04-29
CA2121798C (en) 2007-07-24
NO317625B1 (no) 2004-11-29
JP2877788B2 (ja) 1999-03-31
AU661360B2 (en) 1995-07-20
FI116850B (fi) 2006-03-15
WO1993008207A1 (en) 1993-04-29
EP0897983B1 (en) 2003-05-07
KR100283541B1 (ko) 2001-03-02
ES2198025T3 (es) 2004-01-16
FI981765A0 (fi) 1998-08-17
DE69233402T3 (de) 2009-06-25
EP0897983A3 (en) 1999-03-17
FI981765L (fi) 1998-08-17
NO941422D0 (no) 1994-04-19
JP3308534B2 (ja) 2002-07-29
CA2121798A1 (en) 1993-04-29
EP0667901A4 (en) 1995-06-22
CA2312667C (en) 2002-11-19
EP0897983A2 (en) 1999-02-24
ATE274055T1 (de) 2004-09-15
EP0667901B1 (en) 2004-08-18
FI941837L (fi) 1994-05-30

Similar Documents

Publication Publication Date Title
ATE239790T1 (de) Antikörper gegen cd40-l
DE68902614D1 (de) Akkommodierende intraokulare linse.
DE68916079D1 (de) Intraokulare Linse.
DE3763882D1 (de) Katadioptrische intraokulare linse.
DE69029015D1 (de) Antikörper gegen menschlichen Interleukin-6-Rezeptor
DE3685004D1 (de) Intraokulare linse.
DE68914244D1 (de) Monoklonaler Antikörper.
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
DE69111930D1 (de) Künstlicher Antikörper.
DE69103002D1 (de) Drosselklappe.
FR2677160B1 (fr) Instruments de musique a cordes frottees ou pincees.
MX9205013A (es) Anillo acelerador de flotacion.
FR2700855B1 (fr) Dosage immunométrique d'un antigène ou d'un haptène.
ITPN910039U1 (it) Lavastoviglie con sistema di asciugatura a condensazione
DE68917796D1 (de) Intraokulare Linse.
FI885874A0 (fi) Optisk kopplare.
DE3765979D1 (de) Intraokulare linse mit verminderter blendwirkung.
DE69022361D1 (de) Intraokulare Linse.
NO890116D0 (no) Monoklonale antistoffer.
DE59102018D1 (de) Drosselklappe.
DE68910956D1 (de) Mit toxin modifizierter antikörper.
ITRM920099A0 (it) Antigene 90k associtato a tumori.
DE3768771D1 (de) Faltbare intraokulare linse.
IT223115Z2 (it) Bruciatore a "rampete" con combustione cosiddetta iperstechiometrica
NO910287L (no) Flerfokal intraokulaer linse.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0897983

Country of ref document: EP

RZN Patent revoked